Answers are grounded in this paper and cite their sources.
, focal injections of the PSMA CAR T cells eradicated established human prostate cancer xenografts in a preclinical mouse model. Moreover, systemic intravenous CAR T cell application significantly inhibited tumor growth in combination with non-ablative low-dose docetaxel chemotherapy, while docetaxel or CAR T cell application alone was not effective. In conclusion, the focal application of D7-derived CAR T cells and their combination with chemotherapy represent promising immunotherapeutic avenues to treat local and advanced prostate cancer in the clinic.
No takes yet. Share an insight, caveat, or question.
Alzubi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: